Free Trial

Fate Therapeutics (FATE) Competitors

$4.55
+0.66 (+16.97%)
(As of 07/16/2024 ET)

FATE vs. ADAP, ALLO, BLUE, CLLS, ATRA, BCRX, FDMT, SANA, VIR, and AUTL

Should you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Adaptimmune Therapeutics (ADAP), Allogene Therapeutics (ALLO), bluebird bio (BLUE), Cellectis (CLLS), Atara Biotherapeutics (ATRA), BioCryst Pharmaceuticals (BCRX), 4D Molecular Therapeutics (FDMT), Sana Biotechnology (SANA), Vir Biotechnology (VIR), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.

Fate Therapeutics vs.

Fate Therapeutics (NASDAQ:FATE) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership, community ranking and dividends.

Fate Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.31, meaning that its stock price is 131% more volatile than the S&P 500.

In the previous week, Fate Therapeutics and Fate Therapeutics both had 5 articles in the media. Fate Therapeutics' average media sentiment score of 1.29 beat Adaptimmune Therapeutics' score of 1.13 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adaptimmune Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by insiders. Comparatively, 12.4% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fate Therapeutics currently has a consensus target price of $6.75, indicating a potential upside of 48.35%. Adaptimmune Therapeutics has a consensus target price of $2.79, indicating a potential upside of 119.49%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Adaptimmune Therapeutics is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
Adaptimmune Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Fate Therapeutics received 171 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 68.67% of users gave Fate Therapeutics an outperform vote while only 62.42% of users gave Adaptimmune Therapeutics an outperform vote.

CompanyUnderperformOutperform
Fate TherapeuticsOutperform Votes
480
68.67%
Underperform Votes
219
31.33%
Adaptimmune TherapeuticsOutperform Votes
309
62.42%
Underperform Votes
186
37.58%

Adaptimmune Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$63.53M8.15-$160.93M-$1.92-2.37
Adaptimmune Therapeutics$60.28M5.20-$113.87M-$0.74-1.72

Adaptimmune Therapeutics has a net margin of -890.13% compared to Fate Therapeutics' net margin of -2,933.79%. Fate Therapeutics' return on equity of -46.49% beat Adaptimmune Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-2,933.79% -46.49% -34.48%
Adaptimmune Therapeutics -890.13%-259.68%-61.31%

Summary

Fate Therapeutics beats Adaptimmune Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FATE vs. The Competition

MetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$517.93M$3.04B$5.26B$8.56B
Dividend YieldN/A2.11%2.82%4.03%
P/E Ratio-2.3715.73134.8516.49
Price / Sales8.15345.732,229.4483.17
Price / CashN/A169.7833.0531.33
Price / Book1.224.155.024.64
Net Income-$160.93M-$44.32M$109.37M$215.11M
7 Day Performance45.37%12.20%7.13%7.49%
1 Month Performance26.04%3.61%8.20%7.46%
1 Year Performance-3.81%0.81%8.30%4.76%

Fate Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADAP
Adaptimmune Therapeutics
2.1641 of 5 stars
2.16 / 5 stars
$1.28
+3.2%
$2.79
+117.8%
+41.0%$315.93M$60.28M-1.73449Short Interest ↑
News Coverage
ALLO
Allogene Therapeutics
3.3788 of 5 stars
3.38 / 5 stars
$2.76
+3.0%
$9.95
+260.5%
-29.4%$576.84M$90,000.00-1.54232Positive News
BLUE
bluebird bio
1.7915 of 5 stars
1.79 / 5 stars
$1.22
+8.0%
$5.46
+347.7%
-55.4%$133.40M$3.60M-1.65323Positive News
CLLS
Cellectis
2.2352 of 5 stars
2.24 / 5 stars
$2.09
+4.5%
$8.00
+282.8%
-3.1%$116.16M$9.19M-1.62231Analyst Forecast
News Coverage
Positive News
ATRA
Atara Biotherapeutics
3.5722 of 5 stars
3.57 / 5 stars
$10.47
+3.2%
$700.00
+6,585.8%
-73.2%$50.47M$8.57M-0.20334Positive News
BCRX
BioCryst Pharmaceuticals
4.5568 of 5 stars
4.56 / 5 stars
$7.15
+1.6%
$14.00
+95.8%
+7.0%$1.48B$331.41M-6.68536Positive News
FDMT
4D Molecular Therapeutics
1.4158 of 5 stars
1.42 / 5 stars
$27.22
+5.5%
$45.63
+67.6%
+41.4%$1.41B$20.72M-11.16120Positive News
SANA
Sana Biotechnology
1.8956 of 5 stars
1.90 / 5 stars
$5.95
+5.1%
$12.75
+114.3%
+18.7%$1.32BN/A-3.89328Positive News
VIR
Vir Biotechnology
2.8943 of 5 stars
2.89 / 5 stars
$9.37
+2.3%
$34.14
+264.4%
-55.7%$1.27B$86.18M-2.34587Positive News
AUTL
Autolus Therapeutics
2.6135 of 5 stars
2.61 / 5 stars
$4.25
+2.4%
$8.70
+104.7%
+83.3%$1.13B$1.70M-3.54463Short Interest ↑
High Trading Volume

Related Companies and Tools

This page (NASDAQ:FATE) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners